Digital health company DigiSight Technologies unveiled the Paxos portfolio of products that includes a HIPAA-compliant cloud-based portal, a vision assessment smartphone app, a mobile imaging device, and analytics that, together, allow physicians and researchers to monitor patient data in real time.

“Paxos is a step toward fully realizing the promise of mobile and cloud-based computing in ophthalmology,” said Doug Foster, president and CEO of DigiSight. “We are excited about the potential of our technology to positively impact patient engagement and improve patient care.”

Said mobile app, called Paxos Checkup, is available for iOS and Android, offering patients multiple vision assessments, including a clinically validated visual acuity test and a dynamic Amsler grid. The physician-prescribed app enables patients to test their visual function at home and share results automatically and securely with their physician(s).

On the other hand, Paxos Scope is a hardware add-on with a mobile app that allows healthcare providers to capture ophthalmic photographs of patients anywhere. It is the first and only combined anterior and posterior segment mobile imaging system available for smartphones, incorporating technology licensed from Stanford University.

In February, DigiSight Technologies raised $7.8 million in Series B financing from a number of investors, including Biosys Capital, Waycross Ventures, GE Ventures and Lagunita LLC.